Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its Covid-19 intra-nasal vaccine (BBV154), sources in the company said on Friday.

The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule, they said.